292 related articles for article (PubMed ID: 26895621)
21. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol.
Pérez-Rodríguez E; Martínez-Tadeo JA; Pérez-Rodríguez N; Hernández-Santana G; Callero-Viera A; Rodríguez-Plata E; García-Robaina JC
J Allergy Clin Immunol Pract; 2018; 6(5):1621-1627.e6. PubMed ID: 29361511
[TBL] [Abstract][Full Text] [Related]
22. Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children.
Hong DI; Dioun AF
J Allergy Clin Immunol Pract; 2014; 2(1):13-9; quiz 20. PubMed ID: 24565764
[TBL] [Abstract][Full Text] [Related]
23. Rapid desensitization for hypersensitivity reactions to medications.
Castells M
Immunol Allergy Clin North Am; 2009 Aug; 29(3):585-606. PubMed ID: 19563999
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Antihistamines and Corticosteroids as Premedication in Rapid Drug Desensitization to Paclitaxel: Outcomes in 155 Procedures.
Lopez-Gonzalez P; Madrigal-Burgaleta R; Carpio-Escalona LV; Bernal-Rubio L; Guerra E; Berges-Gimeno MP; Alvarez-Cuesta E
J Allergy Clin Immunol Pract; 2018; 6(4):1356-1362. PubMed ID: 29248386
[TBL] [Abstract][Full Text] [Related]
25. Breakthrough reactions during rapid drug desensitization: Clinical outcome and risk factors.
Kang Y; Kwon OY; Jung H; Kang M; An J; Lee JH; Won HK; Song WJ; Kwon HS; Cho YS; Moon HB; Kim TB
Ann Allergy Asthma Immunol; 2019 Jul; 123(1):48-56.e1. PubMed ID: 31108181
[TBL] [Abstract][Full Text] [Related]
26. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.
Vetter MH; Khan A; Backes FJ; Bixel K; Cohn DE; Copeland LJ; Fowler JM; Salani R; Li Q; O'Malley DM
Gynecol Oncol; 2019 Feb; 152(2):316-321. PubMed ID: 30503265
[TBL] [Abstract][Full Text] [Related]
27. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2005 Nov; 99(2):393-9. PubMed ID: 16054201
[TBL] [Abstract][Full Text] [Related]
28. Desensitization to rituximab in a multidisciplinary setting.
Amorós-Reboredo P; Sánchez-López J; Bastida-Fernández C; do Pazo-Oubiña F; Borràs-Maixenchs N; Giné E; Valero A; Creus-Baró N
Int J Clin Pharm; 2015 Oct; 37(5):744-8. PubMed ID: 25999014
[TBL] [Abstract][Full Text] [Related]
29. Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.
Bonamichi-Santos R; Castells M
Clin Rev Allergy Immunol; 2018 Jun; 54(3):375-385. PubMed ID: 27277133
[TBL] [Abstract][Full Text] [Related]
30. Anaphylaxis to chemotherapy and monoclonal antibodies.
Castells MC
Immunol Allergy Clin North Am; 2015 May; 35(2):335-48. PubMed ID: 25841555
[TBL] [Abstract][Full Text] [Related]
31. Hypersensitivity to antineoplastic agents.
Castells MC
Curr Pharm Des; 2008; 14(27):2892-901. PubMed ID: 18991707
[TBL] [Abstract][Full Text] [Related]
32. Clopidogrel hypersensitivity: a novel multi-day outpatient oral desensitization regimen.
Fajt M; Petrov A
Ann Pharmacother; 2010 Jan; 44(1):11-8. PubMed ID: 20009004
[TBL] [Abstract][Full Text] [Related]
33. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy.
Wang AL; Patil SU; Long AA; Banerji A
Ann Allergy Asthma Immunol; 2015 Nov; 115(5):422-8. PubMed ID: 26298407
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
[TBL] [Abstract][Full Text] [Related]
35. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.
Wong JT; Long A
J Allergy Clin Immunol Pract; 2017; 5(6):1564-1571. PubMed ID: 29122155
[TBL] [Abstract][Full Text] [Related]
36. A new rapid desensitization protocol for chemotherapy agents.
Gastaminza G; de la Borbolla JM; Goikoetxea MJ; Escudero R; Antón J; Espinós J; Lacasa C; Fernández-Benítez M; Sanz ML; Ferrer M
J Investig Allergol Clin Immunol; 2011; 21(2):108-12. PubMed ID: 21462800
[TBL] [Abstract][Full Text] [Related]
37. Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization.
Labella M; Castells M
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):623-629. PubMed ID: 33781937
[TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
Wong JT; Ling M; Patil S; Banerji A; Long A
J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
[TBL] [Abstract][Full Text] [Related]
39. Key elements in hypersensitivity reactions to chemotherapy: experience with rapid drug desensitization in gynaecological cancer in a Tertiary Hospital.
Alen Coutinho I; Costa Sousa F; Cunha F; Frutuoso C; Ribeiro C; Loureiro C; Águas F; Todo Bom A
Eur Ann Allergy Clin Immunol; 2022 Nov; 54(6):265-276. PubMed ID: 33944544
[TBL] [Abstract][Full Text] [Related]
40. Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization.
Rose PG; Metz C; Link N
Int J Gynecol Cancer; 2014 Nov; 24(9):1603-6. PubMed ID: 25304679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
